Herantis Pharma’s financial calendar and annual general meeting for 2023

Herantis Pharma Plc

Company release 15 Dec 2022 at 9:00 am EET


Herantis Pharma Plc (“Herantis”), an innovative biotech company developing new disease-modifying therapies for Parkinson’s disease, hereby publishes the financial calendar for 2023.


Financial year 2022:


Quiet period before 2H and FY 2022 report

February 1 – March 2, 2023

2H and FY 2022 report

March 2, 2023

Annual report 2022

March 28, 2023


Financial year 2023:


Deadline for submission of proposal for AGM

February 20, 2023

Annual General Meeting (AGM)

April 20, 2023

Quiet period before 1H 2023 report

July 23 – August 24, 2023

1H 2023 report

August 24, 2023


The dates are subject to change.



For more information, please contact:

Julie Silber/Gabriela Urquilla

Tel: +46 (0)7 93 486 277/+46 (0)72-396 72 19

Email: ir@herantis.com



About Herantis Pharma Plc

Herantis Pharma Plc is an innovative biotech company developing disease modifying therapies for Parkinson’s Disease. Herantis lead product HER-096, is an advanced small and synthetic chemical peptidomimetic version of the active parent CDNF protein. It combines the compelling mechanism of action of the CDNF protein with the ability to be delivered to the brain via subcutaneous administration.


The shares of Herantis are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden. For more information, please visit https://www.herantis.com.


Certified Advisor: UB Securities Ltd, Finland: +358 9 25 380 225, Sweden: +358 40 5161400

Company website: www.herantis.com